Talk given to the 20th Anniversary Meeting entitled "Development of New Antifungal Drugs adn Combination Therapy" by Director of the National Aspergillosis Centre, Professor David Denning
Long Island Periodontist presents "Appropriate Use of Antibiotics In Dentistry"Edward Brant DDS, MS
Periodontist who does his best when he provides Long Island with treatment for tooth and gum disease. Dentist, dental implants, laser gum treatment for periodontal disease, bone graft, gum surgery
This document discusses the use of antibiotics in oral and maxillofacial surgery. It begins with an introduction and overview of antibiotic classification, mechanisms of action, principles of use, and indications. It then covers specific topics like empirical therapy, combination therapy, special patient populations, surgical wound classification, antibiotic resistance, and newer antibiotics. The key points are that antibiotics are generally used to treat established infections, as prophylaxis for high-risk procedures, and that principles of prudent use include narrow-spectrum therapy based on culture and sensitivity testing when possible.
Antibiotics are chemical substances produced by microorganisms that can kill or inhibit the growth of other microorganisms. This document discusses the appropriate use of antibiotics and antifungals in dentistry. It outlines the cardinal rules for best use of antibiotics, including using the right drug, dose, dosing schedule and duration. It also discusses identifying the type of bacteria present, the appropriate antibiotic to use, and factors specific to the patient. The document also covers the use of topical antibiotics and antifungals, including formulations, indications, durations and treatments for various oral infections caused by Candida.
MDR in Mycobacterium species by Parth AgarwalParth Agarwal
Introduction to MDR and MDR-TB. Types of MDR, History and Diagnostic methods, Antibiotics used and their Mechanism, Mechanism of resistance towards Antibiotics by the bacteria and Future Technologies
This document discusses antibiotics used in dentistry. It begins by defining antibiotics and explaining their early historical use dating back to ancient Greece, India, and Russia where molds and plants were used to treat infections. It then discusses the modern history of antibiotic discovery from Fleming's discovery of penicillin in 1928 to the development of streptomycin, chloramphenicol, and tetracycline in the 1940s-50s. The document goes on to classify antibiotics by their chemical structure, mechanism of action, spectrum of activity, and source. It provides examples of commonly used antibiotics in dentistry like penicillins, cephalosporins, metronidazole, tetracyclines and sulfonamides. It also lists
Principle of antibiotic consideration in odontogenic infection .Diwakar vasudev
This document discusses the diagnosis and treatment of odontogenic infections. It covers the local and systemic signs of infection, causes of depressed host defenses, identification of pathogens, appropriate antibiotic selection, dosage, and treatment considerations. The most common odontogenic infections are usually polymicrobial, involving both aerobic and anaerobic bacteria. Penicillin is often the first-line treatment, but alternatives exist for penicillin allergies. Proper surgical drainage and a full course of antibiotics tailored to the infection are important to achieve resolution.
Antibiotics in oral and maxillofacial surgeryFiras Kassab
This document provides an overview of antibiotic terminology, classification, principles of use and mechanisms of action. It discusses the history of antibiotic discovery and outlines the typical microorganisms responsible for various head and neck infections. Guidelines are provided for evaluating the severity of infection, choosing an appropriate antibiotic based on likely pathogens, and determining when culture and sensitivity testing is needed. The document also reviews antibiotic side effects, resistance and failure as well as special considerations for treatment in pregnancy, renal or hepatic impairment and diabetes.
This document discusses antibiotics prescribing for dentistry. It defines antibiotics and describes how penicillin was discovered by accident. It outlines the risks of antibiotic use including drug resistance, superinfection, toxicity and allergies. Benefits include preventing and spreading of infection. Antibiotics are classified based on their mode of action and therapeutic spectra. Various antibiotics are discussed in terms of their pharmacodynamics, mechanisms of action, indications and principles of use. Factors that influence dosing like renal function are also covered.
Long Island Periodontist presents "Appropriate Use of Antibiotics In Dentistry"Edward Brant DDS, MS
Periodontist who does his best when he provides Long Island with treatment for tooth and gum disease. Dentist, dental implants, laser gum treatment for periodontal disease, bone graft, gum surgery
This document discusses the use of antibiotics in oral and maxillofacial surgery. It begins with an introduction and overview of antibiotic classification, mechanisms of action, principles of use, and indications. It then covers specific topics like empirical therapy, combination therapy, special patient populations, surgical wound classification, antibiotic resistance, and newer antibiotics. The key points are that antibiotics are generally used to treat established infections, as prophylaxis for high-risk procedures, and that principles of prudent use include narrow-spectrum therapy based on culture and sensitivity testing when possible.
Antibiotics are chemical substances produced by microorganisms that can kill or inhibit the growth of other microorganisms. This document discusses the appropriate use of antibiotics and antifungals in dentistry. It outlines the cardinal rules for best use of antibiotics, including using the right drug, dose, dosing schedule and duration. It also discusses identifying the type of bacteria present, the appropriate antibiotic to use, and factors specific to the patient. The document also covers the use of topical antibiotics and antifungals, including formulations, indications, durations and treatments for various oral infections caused by Candida.
MDR in Mycobacterium species by Parth AgarwalParth Agarwal
Introduction to MDR and MDR-TB. Types of MDR, History and Diagnostic methods, Antibiotics used and their Mechanism, Mechanism of resistance towards Antibiotics by the bacteria and Future Technologies
This document discusses antibiotics used in dentistry. It begins by defining antibiotics and explaining their early historical use dating back to ancient Greece, India, and Russia where molds and plants were used to treat infections. It then discusses the modern history of antibiotic discovery from Fleming's discovery of penicillin in 1928 to the development of streptomycin, chloramphenicol, and tetracycline in the 1940s-50s. The document goes on to classify antibiotics by their chemical structure, mechanism of action, spectrum of activity, and source. It provides examples of commonly used antibiotics in dentistry like penicillins, cephalosporins, metronidazole, tetracyclines and sulfonamides. It also lists
Principle of antibiotic consideration in odontogenic infection .Diwakar vasudev
This document discusses the diagnosis and treatment of odontogenic infections. It covers the local and systemic signs of infection, causes of depressed host defenses, identification of pathogens, appropriate antibiotic selection, dosage, and treatment considerations. The most common odontogenic infections are usually polymicrobial, involving both aerobic and anaerobic bacteria. Penicillin is often the first-line treatment, but alternatives exist for penicillin allergies. Proper surgical drainage and a full course of antibiotics tailored to the infection are important to achieve resolution.
Antibiotics in oral and maxillofacial surgeryFiras Kassab
This document provides an overview of antibiotic terminology, classification, principles of use and mechanisms of action. It discusses the history of antibiotic discovery and outlines the typical microorganisms responsible for various head and neck infections. Guidelines are provided for evaluating the severity of infection, choosing an appropriate antibiotic based on likely pathogens, and determining when culture and sensitivity testing is needed. The document also reviews antibiotic side effects, resistance and failure as well as special considerations for treatment in pregnancy, renal or hepatic impairment and diabetes.
This document discusses antibiotics prescribing for dentistry. It defines antibiotics and describes how penicillin was discovered by accident. It outlines the risks of antibiotic use including drug resistance, superinfection, toxicity and allergies. Benefits include preventing and spreading of infection. Antibiotics are classified based on their mode of action and therapeutic spectra. Various antibiotics are discussed in terms of their pharmacodynamics, mechanisms of action, indications and principles of use. Factors that influence dosing like renal function are also covered.
This document discusses antibiotic use in dentistry. It covers principles of therapy and antibiotic selection including using the most specific antibiotic, proper administration, and patient monitoring. It then describes common antibiotic classes used in dentistry like beta-lactams (penicillins, cephalosporins), tetracyclines, vancomycin, macrolides, nitroimidazoles, and quinolones. It provides examples of antibiotics used to treat maxillofacial infections and conditions. Finally, it discusses antibiotic prophylaxis for dental procedures in patients with conditions like cardiac abnormalities or compromised immunity.
This document provides an overview of antibiotics used to treat maxillofacial infections. It discusses the history and classification of antibiotics, principles for choosing the appropriate antibiotic, administration of antibiotics, combination antibiotic therapy, antibiotic prophylaxis and its principles. It also discusses some of the most commonly used antibiotics for maxillofacial infections such as penicillin, cephalosporins, and tetracyclines. Specific antibiotics discussed in more detail include amoxicillin, penicillin VK, and minocycline.
This document discusses various classes of antibiotics including aminoglycosides, carbapenems, cephalosporins, erythromycins, and penicillins. It provides details on the mechanism of action, spectrum of activity, therapeutic uses, and precautions for each class. The main classes of antibiotics covered are defined by their chemical structure and each class generally has a different range of antibacterial activity. Common examples of drugs within each class are also listed along with their dosages and routes of administration.
This document discusses various biologic therapies for treating severe asthma, including anti-IgE, anti-IL5, and anti-IL4 receptor therapies. It provides details on currently approved therapies such as omalizumab, mepolizumab, benralizumab, dupilumab, and reslizumab. For each therapy, it outlines the mechanisms of action, clinical trial results demonstrating efficacy in reducing exacerbations and corticosteroid use, safety profiles, and criteria for use in treating severe eosinophilic asthma. It also compares the potential advantages of different anti-IL5 biologics like benralizumab.
The Indian Dental Academy is the Leader in continuing dental education , training dentists in all aspects of dentistry and
offering a wide range of dental certified courses in different formats.
This document provides guidelines for rational antibiotic therapy. It discusses the importance of rational antibiotic use to better care for patients, combat antimicrobial resistance, and reduce costs. It outlines strategies for choosing the appropriate antibiotic based on diagnosis, likely pathogens, sensitivity patterns, and patient factors. Specific antibiotic recommendations are provided for common bacterial infections affecting various body systems like skin, ENT, respiratory, GI, urinary, CNS, and cardiovascular. It also discusses approaches for antibiotic prophylaxis and strategies to prevent antibiotic resistance.
The Indian Dental Academy is the Leader in continuing dental education , training dentists in all aspects of dentistry and
offering a wide range of dental certified courses in different formats.
This document discusses antibiotics used in pediatrics, including tetracyclines, aminoglycosides, and macrolides. It provides details on specific antibiotics like tetracycline, streptomycin, and amikacin. It describes the sources, mechanisms of action, indications, absorption and excretion, adverse effects, and contraindications of these important antibiotic classes used to treat pediatric infections.
Hi, I am Dr Komal Ghiya, pediatric dentist by profession, I am here to share some of my own presentations for educational purposes. I hope you a presentation on ANTIBIOTICS IN PEDIATRIC DENTISTRY will be useful for all the dental and medical students. Comments are welcome if you like the presentations and if not please suggest some ways I could make them better for you. All the best
Vancomycin is the drug of choice for MRSA infections. Clindamycin can be used in this case since the culture showed sensitivity to clindamycin. Clindamycin is an acceptable alternative to vancomycin for skin and soft tissue infections caused by MRSA.
The document provides a detailed review of antibiotics, including:
1) It traces the history of antibiotics from sulfonamides in the 1930s to newer drugs developed in response to increasing bacterial resistance in the 1960s and onward.
2) It describes different classes of antibiotics like beta-lactams (penicillins and cephalosporins) and summarizes the characteristics, uses, and limitations of representative drugs within each class.
3) It discusses the ongoing challenge of bacterial resistance developing to existing antibiotics and the need for prudent antibiotic use and new drug development to address this threat.
This document summarizes information about invasive fungal infections in transplant patients and compares the antifungal drugs micafungin and caspofungin. Key points:
- Invasive fungal infections are a significant problem and risk for transplant patients due to health status and immunosuppression.
- Candida and Aspergillus species are common causes and mortality from fungal infections ranges from 25-80%.
- Micafungin, caspofungin, and anidulafungin are echinocandin antifungals that inhibit fungal cell wall synthesis. A phase III trial found similar treatment success rates for micafungin and caspofungin in treating invasive candidiasis.
Guidelines For Antibiotic Use by doctor SaleemMuhammad Saleem
Antibiotic guidelines in surgery,
especially antibiotic prophylaxis.
Prophylactic antibiotics in general surgery, cardiothoracic, vascular, orthopedic,neurosurgery,
Classification of wounds.
Guidelines of prophylactic antibiotics
By doctor Saleem
https://www.saleemplasticsurgeon.com/
1. Antibiotics are chemical substances produced by microorganisms like fungi, actinomycetes and bacteria that suppress or destroy other microorganisms.
2. Alexander Fleming discovered penicillin in 1929 after noticing that a mold growing in one of his petri dishes had prevented bacteria from growing nearby. Penicillin revolutionized medicine as the first widely used antibiotic.
3. Antibiotic resistance has become a major problem as bacteria have increasingly developed resistance, even to formerly powerful antibiotics like penicillin. Proper antibiotic stewardship including only using antibiotics when necessary and completing prescribed treatment courses can help address this growing threat.
This document discusses various studies on the use of antibiotic prophylaxis in different dental procedures and conditions. It summarizes several randomized controlled trials that evaluated the effectiveness of short-term versus long-term antibiotic regimens for procedures like orthognathic surgery and mandible fracture treatment, and whether they reduce postoperative infection rates. It also reviews evidence that supports the use of preoperative antibiotic prophylaxis for third molar surgery and clean neck dissections to lower risks of infection.
This document discusses the treatment of tuberculosis. It covers short course chemotherapy which involves a 6 month regimen divided into two phases. The first phase kills most mycobacteria and the second eliminates remaining bacteria. Directly Observed Treatment, Short course (DOTS) involves administering drugs under supervision. First and second line drugs for tuberculosis are listed along with their side effects. Treatment regimens for drug susceptible, multi-drug resistant, and extremely drug resistant tuberculosis according to the Revised National Tuberculosis Control Program are outlined.
To sum up, the risk/benefit ratio should be always weighed before prescribing antibiotics.
Appropriately selected patients will benefit from systemically administered antibiotics.
A restrictive and conservative use of antibiotics is highly recommended in endodontic practice, but indiscriminate use is contrary to sound clinical practice
Future generations will thank us for today’s conscientious and judicious use of antibiotics
Tuberculosis is a chronic infectious disease caused by Mycobacterium tuberculosis. It commonly affects the lungs but can spread to other organs. Diagnosis involves sputum microscopy, culture, and molecular testing. Standard treatment for drug-susceptible TB involves a two-month intensive phase of isoniazid, rifampin, pyrazinamide, and ethambutol followed by a four-month continuation phase of isoniazid and rifampin. Multidrug-resistant TB requires treatment with second-line drugs for up to 24 months. Preventive measures include Bacille Calmette-Guérin vaccination and isoniazid treatment for latent infections. Global efforts aim to end the TB epidemic
Management of Chronic Pulmonary Aspergillosis and IgE for the LaypersonGraham Atherton
Professor Denning summarises how we manage CPA at the National Aspergillosis Centre, what we have learned, what we are still learning.
Graham Atherton describes IgE and how it affects Aspergillosis
Formulation and Evaluation of Dental gel containing Clove oil for the treatme...Shaik Sana
The document describes a study that aimed to develop and evaluate a dental gel containing clove oil for the treatment of periodontitis. Several gel formulations were prepared using clove oil as the active ingredient, carbopol 934 as the gelling agent, and other excipients. The clove oil was characterized. The gels were evaluated for various properties such as pH, viscosity, spreadability, extrudability and antimicrobial activity. Formulation F3 showed the best results and was concluded to be a suitable gel for the treatment of periodontitis based on its physicochemical properties and antimicrobial activity against periodontal pathogens.
This document discusses antibiotic use in dentistry. It covers principles of therapy and antibiotic selection including using the most specific antibiotic, proper administration, and patient monitoring. It then describes common antibiotic classes used in dentistry like beta-lactams (penicillins, cephalosporins), tetracyclines, vancomycin, macrolides, nitroimidazoles, and quinolones. It provides examples of antibiotics used to treat maxillofacial infections and conditions. Finally, it discusses antibiotic prophylaxis for dental procedures in patients with conditions like cardiac abnormalities or compromised immunity.
This document provides an overview of antibiotics used to treat maxillofacial infections. It discusses the history and classification of antibiotics, principles for choosing the appropriate antibiotic, administration of antibiotics, combination antibiotic therapy, antibiotic prophylaxis and its principles. It also discusses some of the most commonly used antibiotics for maxillofacial infections such as penicillin, cephalosporins, and tetracyclines. Specific antibiotics discussed in more detail include amoxicillin, penicillin VK, and minocycline.
This document discusses various classes of antibiotics including aminoglycosides, carbapenems, cephalosporins, erythromycins, and penicillins. It provides details on the mechanism of action, spectrum of activity, therapeutic uses, and precautions for each class. The main classes of antibiotics covered are defined by their chemical structure and each class generally has a different range of antibacterial activity. Common examples of drugs within each class are also listed along with their dosages and routes of administration.
This document discusses various biologic therapies for treating severe asthma, including anti-IgE, anti-IL5, and anti-IL4 receptor therapies. It provides details on currently approved therapies such as omalizumab, mepolizumab, benralizumab, dupilumab, and reslizumab. For each therapy, it outlines the mechanisms of action, clinical trial results demonstrating efficacy in reducing exacerbations and corticosteroid use, safety profiles, and criteria for use in treating severe eosinophilic asthma. It also compares the potential advantages of different anti-IL5 biologics like benralizumab.
The Indian Dental Academy is the Leader in continuing dental education , training dentists in all aspects of dentistry and
offering a wide range of dental certified courses in different formats.
This document provides guidelines for rational antibiotic therapy. It discusses the importance of rational antibiotic use to better care for patients, combat antimicrobial resistance, and reduce costs. It outlines strategies for choosing the appropriate antibiotic based on diagnosis, likely pathogens, sensitivity patterns, and patient factors. Specific antibiotic recommendations are provided for common bacterial infections affecting various body systems like skin, ENT, respiratory, GI, urinary, CNS, and cardiovascular. It also discusses approaches for antibiotic prophylaxis and strategies to prevent antibiotic resistance.
The Indian Dental Academy is the Leader in continuing dental education , training dentists in all aspects of dentistry and
offering a wide range of dental certified courses in different formats.
This document discusses antibiotics used in pediatrics, including tetracyclines, aminoglycosides, and macrolides. It provides details on specific antibiotics like tetracycline, streptomycin, and amikacin. It describes the sources, mechanisms of action, indications, absorption and excretion, adverse effects, and contraindications of these important antibiotic classes used to treat pediatric infections.
Hi, I am Dr Komal Ghiya, pediatric dentist by profession, I am here to share some of my own presentations for educational purposes. I hope you a presentation on ANTIBIOTICS IN PEDIATRIC DENTISTRY will be useful for all the dental and medical students. Comments are welcome if you like the presentations and if not please suggest some ways I could make them better for you. All the best
Vancomycin is the drug of choice for MRSA infections. Clindamycin can be used in this case since the culture showed sensitivity to clindamycin. Clindamycin is an acceptable alternative to vancomycin for skin and soft tissue infections caused by MRSA.
The document provides a detailed review of antibiotics, including:
1) It traces the history of antibiotics from sulfonamides in the 1930s to newer drugs developed in response to increasing bacterial resistance in the 1960s and onward.
2) It describes different classes of antibiotics like beta-lactams (penicillins and cephalosporins) and summarizes the characteristics, uses, and limitations of representative drugs within each class.
3) It discusses the ongoing challenge of bacterial resistance developing to existing antibiotics and the need for prudent antibiotic use and new drug development to address this threat.
This document summarizes information about invasive fungal infections in transplant patients and compares the antifungal drugs micafungin and caspofungin. Key points:
- Invasive fungal infections are a significant problem and risk for transplant patients due to health status and immunosuppression.
- Candida and Aspergillus species are common causes and mortality from fungal infections ranges from 25-80%.
- Micafungin, caspofungin, and anidulafungin are echinocandin antifungals that inhibit fungal cell wall synthesis. A phase III trial found similar treatment success rates for micafungin and caspofungin in treating invasive candidiasis.
Guidelines For Antibiotic Use by doctor SaleemMuhammad Saleem
Antibiotic guidelines in surgery,
especially antibiotic prophylaxis.
Prophylactic antibiotics in general surgery, cardiothoracic, vascular, orthopedic,neurosurgery,
Classification of wounds.
Guidelines of prophylactic antibiotics
By doctor Saleem
https://www.saleemplasticsurgeon.com/
1. Antibiotics are chemical substances produced by microorganisms like fungi, actinomycetes and bacteria that suppress or destroy other microorganisms.
2. Alexander Fleming discovered penicillin in 1929 after noticing that a mold growing in one of his petri dishes had prevented bacteria from growing nearby. Penicillin revolutionized medicine as the first widely used antibiotic.
3. Antibiotic resistance has become a major problem as bacteria have increasingly developed resistance, even to formerly powerful antibiotics like penicillin. Proper antibiotic stewardship including only using antibiotics when necessary and completing prescribed treatment courses can help address this growing threat.
This document discusses various studies on the use of antibiotic prophylaxis in different dental procedures and conditions. It summarizes several randomized controlled trials that evaluated the effectiveness of short-term versus long-term antibiotic regimens for procedures like orthognathic surgery and mandible fracture treatment, and whether they reduce postoperative infection rates. It also reviews evidence that supports the use of preoperative antibiotic prophylaxis for third molar surgery and clean neck dissections to lower risks of infection.
This document discusses the treatment of tuberculosis. It covers short course chemotherapy which involves a 6 month regimen divided into two phases. The first phase kills most mycobacteria and the second eliminates remaining bacteria. Directly Observed Treatment, Short course (DOTS) involves administering drugs under supervision. First and second line drugs for tuberculosis are listed along with their side effects. Treatment regimens for drug susceptible, multi-drug resistant, and extremely drug resistant tuberculosis according to the Revised National Tuberculosis Control Program are outlined.
To sum up, the risk/benefit ratio should be always weighed before prescribing antibiotics.
Appropriately selected patients will benefit from systemically administered antibiotics.
A restrictive and conservative use of antibiotics is highly recommended in endodontic practice, but indiscriminate use is contrary to sound clinical practice
Future generations will thank us for today’s conscientious and judicious use of antibiotics
Tuberculosis is a chronic infectious disease caused by Mycobacterium tuberculosis. It commonly affects the lungs but can spread to other organs. Diagnosis involves sputum microscopy, culture, and molecular testing. Standard treatment for drug-susceptible TB involves a two-month intensive phase of isoniazid, rifampin, pyrazinamide, and ethambutol followed by a four-month continuation phase of isoniazid and rifampin. Multidrug-resistant TB requires treatment with second-line drugs for up to 24 months. Preventive measures include Bacille Calmette-Guérin vaccination and isoniazid treatment for latent infections. Global efforts aim to end the TB epidemic
Management of Chronic Pulmonary Aspergillosis and IgE for the LaypersonGraham Atherton
Professor Denning summarises how we manage CPA at the National Aspergillosis Centre, what we have learned, what we are still learning.
Graham Atherton describes IgE and how it affects Aspergillosis
Formulation and Evaluation of Dental gel containing Clove oil for the treatme...Shaik Sana
The document describes a study that aimed to develop and evaluate a dental gel containing clove oil for the treatment of periodontitis. Several gel formulations were prepared using clove oil as the active ingredient, carbopol 934 as the gelling agent, and other excipients. The clove oil was characterized. The gels were evaluated for various properties such as pH, viscosity, spreadability, extrudability and antimicrobial activity. Formulation F3 showed the best results and was concluded to be a suitable gel for the treatment of periodontitis based on its physicochemical properties and antimicrobial activity against periodontal pathogens.
This document discusses various fungal infections that can affect the oral cavity and respiratory tract, including candidiasis, aspergillosis, and zygomycosis. It describes the characteristics and morphology of fungi, including molds, yeasts, dimorphic fungi. It then covers the pathogenesis, clinical manifestations, diagnosis and treatment of the main opportunistic fungal infections.
This document discusses various antifungal agents including their classification, mechanisms of action, and uses. It covers several classes of antifungals such as polyenes (e.g. amphotericin B), azoles (e.g. fluconazole, itraconazole), and echinocandins (e.g. caspofungin). It also discusses the antifungal spectra, pharmacokinetics, advantages/disadvantages, and adverse effects of different antifungal drugs. The document provides a comprehensive overview of the major antifungal agents used in clinical practice.
This document contains a medical assessment of a patient's gait and mobility. It includes questions about the patient's use of assistive devices, including canes, orthopedic shoes, and prosthetics. The physician examines the patient's gait both with and without assistive devices, noting any abnormalities, limb weakness, or other issues that impact mobility. Medical findings are recorded, such as muscle atrophy, spasticity, or involuntary movements. The physician determines if prescriptions for assistive devices or prosthetics are needed.
Aspergillosis Support Meeting (Christmas Quiz) Dec 2011Graham Atherton
The document appears to be the agenda and quiz for a Christmas support meeting held by the National Aspergillosis Centre (NAC) in Manchester. The meeting included an introduction by Chris Harris, the NAC Centre Manager, followed by a quiz on aspergillosis and the work of the NAC. There was also a discussion period for any other business before closing. The quiz covered topics like the types of aspergillosis, symptoms, diagnosis and treatment as well as facts about the work of the NAC.
1) The document discusses HTML5 and the W3C standards process. It notes that HTML5 is still a work in progress at the W3C, going through the recommendation process.
2) Details are provided about the different W3C working groups involved in developing standards like HTML5, and how interested parties can get involved through groups like the Japanese Interest Group.
3) An overview is given of the W3C technical architecture group work plan, touching on past efforts like XHTML and future efforts to link data on the web through standards like schema.org and the linked open data cloud.
This document summarizes key concepts around unemployment, including how it is measured, types of unemployment (such as frictional, cyclical, and structural), and factors that influence wages and unemployment rates. It provides unemployment rates for Saudi Arabia, the US, and China. It also discusses the labor force, labor force participation rates, unemployment insurance programs, and concepts like the natural rate of unemployment, efficiency wages, and the impact of minimum wages.
El 14 de noviembre de 1910, Eugene Ely realizó el primer despegue de un avión desde un buque de guerra, el USS Birmingham. Voló unas dos millas antes de aterrizar en tierra. Luego, el 18 de enero de 1911, Ely aterrizó con el mismo avión sobre el USS Pennsylvania, logrando el primer aterrizaje sobre un buque de guerra, demostrando la viabilidad de las operaciones aéreas desde barcos.
MahalaMobile provides mobile development and marketing services including custom mobile site design and development, mobile ad serving and targeting, SMS marketing, and mobile analytics reporting. They help clients build a powerful mobile communication channel and ensure all campaigns follow best practices. Some of their services include mobi sites with device detection and rendering, opt-in forms, SMS and multimedia modules, and mobile analytics.
The document discusses foreign exchange trading and provides an introduction to the forex market. It describes the forex market as the largest financial market in the world, with daily trading volumes of $4.2 trillion. Participants include banks, corporations, money managers, and individual investors. The forex market operates as a 24-hour global market each day. While requiring a minimum deposit of $5,000, forex trading allows for leverage of up to 50:1. Risk is managed through stop-loss orders to limit potential losses. Technical analysis of charts and patterns is used to identify trading opportunities.
The document describes an upcoming urban mobility event called Autonomy Paris 2016 that will take place from October 6-9, 2016 at the Grande Halle in Paris. The event will showcase innovative multi-modal mobility solutions from companies in areas like car sharing, biking, scooters and driverless vehicles. It aims to connect exhibitors with an audience of innovators, urbanites, and policymakers. The event will include showcasing solutions, test tracks, conferences, and networking opportunities over its 4 day program. The organizers have experience in events and understand urban audiences, with the goal of inspiring attendees and helping mobility providers connect with potential partners and customers.
Fungal infections range from mild and superficial to life-threatening in immunocompromised individuals. Antifungal agents work by exploiting differences between fungal and mammalian cells, targeting the fungal cell membrane or DNA synthesis. Therapies include polyene antifungals like amphotericin B that damage fungal membranes, azoles like fluconazole that inhibit ergosterol synthesis, and antimetabolites like 5-fluorocytosine that inhibit fungal DNA/RNA synthesis. Treatment involves prophylaxis for high-risk groups, preemptive therapy based on colonization markers, empiric therapy for suspected infection, and specific therapy targeted to identified pathogens. Clinical trials of antifungal
Community-acquired respiratory tract infections (CARTIs) are common causes of illness that are difficult to treat due to a range of possible pathogens and increasing antibiotic resistance. Quinolones have evolved over generations to provide broad-spectrum activity against both gram-positive and gram-negative bacteria involved in CARTIs. They inhibit bacterial DNA replication and have excellent pharmacokinetic properties allowing once-daily oral or IV dosing. Clinical studies demonstrate that newer quinolones like moxifloxacin effectively treat CARTIs and reduce recovery time, hospital stays, and healthcare costs compared to other antibiotic regimens.
This document discusses best practices for allergen immunotherapy. It provides an overview of its effectiveness for treating allergic rhinitis, asthma, and venom hypersensitivity based on updated meta-analyses. Guidelines developed by WHO and allergy societies recommend immunotherapy for patients who have not responded adequately to medications or avoidance measures. Precautions are discussed for special groups like children, pregnant women, and elderly patients. The document also covers patient selection, product preparation, dosing schedules, safety considerations, and managing treatment.
This document provides an overview of antifungal drugs presented by Nehal M. Ramadan. It categorizes antifungal drugs, describes their mechanisms of action, pharmacokinetics, interactions, side effects, and clinical uses. The drugs discussed include azoles, polyenes, echinocandins, flucytosine, and griseofulvin. Amphotericin B is used for severe fungal infections while azoles are used for less severe cases. Newer antifungals like posaconazole, voriconazole and caspofungin are used as salvage therapy. Flucytosine is administered with amphotericin B for synergistic treatment
This document discusses various antifungal agents including polyenes, azoles, and one antimetabolite. It describes key properties of major drug classes like polyenes including amphotericin B and nystatin, which interact with ergosterol in fungal cell membranes. Azoles like fluconazole and itraconazole inhibit ergosterol synthesis. 5-fluorocytosine is an antimetabolite that inhibits DNA and RNA synthesis in fungi. The document provides details on the mechanisms, uses, and limitations of these major antifungal drug classes and agents.
Allergic bronchopulmonary aspergillosis (ABPA) is a hypersensitivity reaction to the fungus Aspergillus fumigatus in patients with asthma or cystic fibrosis. It occurs in 1-2% of asthmatics and 1-15% of cystic fibrosis patients. Clinical features include recurrent asthma exacerbations, cough, wheezing and blood-stained sputum. Diagnosis is based on clinical criteria and elevated IgE levels. Treatment involves oral corticosteroids, antifungal agents like itraconazole, and omalizumab for severe cases. Prognosis depends on early diagnosis and treatment to prevent lung damage.
This document discusses antibiotics used in periodontics. It defines key terms like antibiotic, antimicrobial, and provides classifications of antibiotics based on chemical structure, mechanism of action, spectrum of activity, and source. It outlines guidelines for antibiotic use in periodontal disease, including indications, choosing an antibiotic based on patient and microbe factors, dosing principles, and duration of therapy. Systemic and local antibiotic administration methods are discussed. Common antibiotics used in periodontics that have been extensively evaluated are also listed.
Fungal infections have increased due to medical advances and immunosuppression. They are difficult to treat because fungi grow slowly and infect tissues poorly penetrated by drugs. The main antifungal drug classes are polyenes, azoles, and echinocandins. Polyenes like amphotericin B bind ergosterol in fungal membranes, causing leakage. Azoles like fluconazole inhibit ergosterol synthesis. Echinocandins prevent fungal cell wall synthesis. Drug choice depends on infection severity, location, and fungal species. Long-term treatment is usually needed.
Systemic antimicrobial therapy in periodontal diseases (3).pptmalti19
This document discusses the use of chemotherapeutic agents, specifically antimicrobial agents, for the treatment of periodontal diseases. It provides background on antimicrobial agents including antibiotics, antiseptics, and disinfectants. It then focuses on the use of two common antimicrobial agents used as adjuncts to mechanical debridement for periodontal therapy - metronidazole and tetracyclines. For both agents, it discusses their mechanisms of action, efficacy evidence from studies on types of periodontal diseases, advantages, limitations and side effects.
1) The document discusses the impact of antimicrobial resistance on the treatment of invasive pneumococcal infections.
2) It notes that while penicillin was once highly effective at treating pneumococcal infections, resistance has increased significantly worldwide over the past few decades, particularly for penicillin and other beta-lactam antibiotics.
3) The epidemiology of penicillin-nonsusceptible Streptococcus pneumoniae (PNSP) is examined, finding high rates of resistance in many parts of the world, especially in the respiratory tract where resistance is most prevalent.
This document provides an overview of antibiotics used in periodontics. It begins with an introduction to antibiotics and their historical background. It then covers classification of antimicrobial agents based on chemical structure, mechanism of action, organisms targeted, and spectrum of activity. Guidelines for antibiotic use in periodontal diseases are presented, along with the diseases where antibiotics can be used. Commonly used antibiotics like tetracycline, doxycycline, metronidazole, penicillin, and amoxicillin-clavulanate are described in detail. The document concludes with a reference to research on systemic antibiotic use in periodontics.
Cefpodoxime has in vitro activity against common respiratory pathogens like Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Clinical studies show cefpodoxime is effective in treating acute otitis media, sinusitis, and tonsillopharyngitis. If used carefully, cefpodoxime can be considered an alternative treatment for respiratory infections where penicillins and macrolides have reduced efficacy due to increasing bacterial resistance.
This document discusses adjuvant medications in the treatment of pemphigus vulgaris. It begins with definitions and epidemiology of pemphigus vulgaris. It then discusses diagnostic features such as clinical manifestations involving mucous membranes and skin. Management is focused on using corticosteroids as the primary treatment along with immunosuppressive drugs as adjuvants to reduce steroid dosage and side effects. Newer treatments discussed include rituximab and mycophenolate mofetil. Prognosis is generally good with treatment but mucosal lesions can be recalcitrant.
The document discusses various antifungal drugs used to treat fungal infections. It describes the different types of fungal infections including superficial and systemic infections. It provides details on the most common fungal pathogens that cause infections. The mechanisms of action and spectra of various classes of antifungal drugs are summarized, including polyene antibiotics like amphotericin B and azoles like fluconazole and itraconazole. Adverse effects and drug interactions of these antifungals are also mentioned.
Study on Sensitivity Pattern of Micro-Organisms in Respiratory Tract Infectio...iosrjce
Wide reports in literatures from different parts of the world revealed that antibiotics are
used both widely and indiscriminately. RTIs comprise the most common indication for consulting a general
practitioner, and obtaining an antibiotic prescription.
This document discusses antifungal drugs used to treat invasive fungal infections in the intensive care unit (ICU). It covers the epidemiology of fungal infections, the mechanisms and targets of different antifungal drug classes, resistance mechanisms, side effects and drug interactions. It reviews the evidence for different antifungal therapies and discusses expert opinions on the use of echinocandins to treat invasive candidiasis in ICU patients.
This document discusses the use of antibiotics in pediatric dentistry. It begins with an introduction to antibiotics and their history. It then covers fundamental concepts of antibiotic therapy including choosing antibiotics based on the pathogen and host. Common antibiotics used in pediatric dentistry are discussed, including amoxicillin, cephalosporins, metronidazole, and combinations. Dosages for various pediatric age groups are provided. The document stresses the importance of proper antibiotic selection and usage to minimize resistance and maximize efficacy in pediatric patients.
Srishti Bhargav presented an overview of anti-protozoal drugs. Many effective drugs are toxic and drug resistance is a major challenge. New drugs are needed with novel mechanisms of action. Several drugs discussed include paromomycin for giardiasis, piperaquine for malaria, posaconazole for fungal infections, and albaconazole which is in pre-clinical trials. Developing tools to detect resistance early and rational drug use and combinations can help address the threat of resistance in protozoal diseases.
Similar to Fungal Research Trust 20th Anniversary Meeting June 2011 - Professor David Denning (20)
Danielle Yuill: Giving patients a VOICE project (Patients helping in research at NAC) http://www.uhsm.nhs.uk/racrf/Pages/involved.aspx.
NB this meeting was confidential so audio is not broadcast in the second part of this support meeting.
A discussion to collect ideas and discuss the forthcoming new handout for the purpose of communicating our support with patients who do not use computers
Pseudomonas infections and a new type of antifungal drugGraham Atherton
This document provides an agenda and information for a support meeting for aspergillosis patients and carers. The meeting will be led by Graham Atherton and supported by Chris Harris from the NAC Centre. The agenda includes presentations on new antifungal medications, itraconazole as a potential anticancer drug, and Pseudomonas bacteria by Pippa Newton from the National Aspergillosis Centre. There will also be a question and answer session.
Aspergillosis Support Group Christmas Quiz 2013Graham Atherton
The December meeting of the Aspergillosis Support Group for Patients & Carers is a quiz played for the David MacIntyre Trophy. Questions are based around the information presented in the previous years meeting and other information about aspergillosis. See how you do!
Poet in Residence Caroline Hawkridge talks about our achievements in holding events to raise awareness of fungal infections using poetry written with patients & carers at earlier meetings.
Graham Atherton talked about GAFFI and about how antifungal drugs work to kill fungal infections
Involving Patients (and carers) in research at NWLC & NACGraham Atherton
Danielle Yuill tells us about her project to discover how best to involve patients and carers in research at the North West Lung Centre & National Aspergillosis Centre - amd not just reviewing grant requests and providing tissue samples.
Graham Atherton takes us through some of the many features & structures we can see in a lung x-ray - what does aspergillosis look like??.
Comparing parts of UK & US Healthcare systems, IgG explainedGraham Atherton
NAC consultant Eavan Muldoon introduces herself as our new medic and talks a little about her background, part of which was spent at Tufts Medical Centre, Boston, USA. Then Graham Atherton talks about IgG, what they are and how they work.
- The document discusses a support meeting for aspergillosis patients and carers. It includes an agenda with presentations on new NHS structures, changes in commissioning of specialized services like the National Aspergillosis Centre, and a Q&A session.
- Graham Atherton will present on funding streams for treatment which may change between clinical commissioning groups and specialized commissioning.
- Any changes from the patient perspective will be minor, with the main difference being funding approval processes for expensive antifungal drugs.
Steve Webster of the Manchester Carers Centre, UK talks about the support and services offered by the centre in Manchester and the other centres throughout the UK. Graham Atherton talks about our progress in the understanding of the health effects caused by damp homes, and how to avoid them!
Chronic illness health psychologist Alison Wearden talks about how stress effects our health and our recovery from illness, and specialist physiotherapist Phil Langridge talks about breathlessness and what we can do to control it.
Graham Atherton discusses gardening for those with allergies, the signs of heart disorder to be aware of if you are taking itraconazole and advice on travel.
Dr Mike Bromley talks about the role of Manchester University in the research and development of new antifungal drugs, followed by Dr Iain Page talking about our research projects in Africa that have the potential to reveal much larger numbers of people suffering from Chronic Pulmonary Aspergillosis (CPA) than is currently thought.
Creative Writing Projects at the National Aspergillosis CentreGraham Atherton
This document discusses using creative projects to raise public awareness of Aspergillosis and the North American Coccidioidomycosis (NAC) clinic. It provides examples of poems written by patients that could be used in newsletters, leaflets, and the clinic waiting room. It also announces an upcoming poetry event and suggests helping patients write and collect their own stories and poems.
Maintaining or Improving your health status in CPA (Khaled Al-shair)Graham Atherton
This document summarizes a presentation on factors affecting health status in chronic pulmonary aspergillosis. The presentation discusses that approximately 70% of patients responded positively to antifungal treatment, while 30% deteriorated. Important factors influencing response and health include underlying diseases, smoking, physical activity, age, nutrition status, and acute chest infections. Previous tuberculosis, asthma, COPD, and pneumonia are common underlying conditions. Smoking negatively impacts lung function, and physical activity is important for health. Nutrition and avoiding chest infections also impact health status in patients with chronic pulmonary aspergillosis.
Dr Libby Radcliffe talks about the aches & pains suffered by aspergillosis patients, the different causes and what can be done to reduce them. Professor Malcolm Richardson talks about the types of moulds we all come across every day and the damage they can cause in the wrong places. Dr Graham Atherton talks about the correct specification for facemasks used to reduce the inhalation of mould spores when carrying out routine daily tasks & hobbies.
Support meeting for aspergillosis patients with Paul Bowyer, Senior Scientist on recent advances in research on susceptibility to Chronic Pulmonary Aspergillosis
Some of the latest progress for the prevention, diagnosis and treatment of as...Graham Atherton
This document summarizes a support meeting for patients with aspergillosis led by Graham Atherton and supported by Marie Kirwan, Georgina Powell, and Debbie Kennedy. The meeting covered advances in prevention, detection, and treatment of aspergillosis, including identifying vulnerable individuals, preventing exposure to resistant strains, improving diagnosis, developing new drugs and treatments like nanotechnology, and exploring stem cell research and the possibility of growing new lungs. The meeting also discussed changes to the Fungal Research Trust becoming the Fungal Infection Trust and improvements to future patient support meetings.
Chronic Cough: What it is and how to try to reduce its impact on your lifeGraham Atherton
This document summarizes a support meeting for patients with aspergillosis. The meeting will be led by Graham Atherton and supported by Marie Kirwan, Georgina Powell, and Debbie Kennedy. It will include an introduction, a presentation on cough by Dr. Jaclyn Smith, a break for tea and coffee, an announcement of changes to the meeting, and will conclude at 3pm. The meeting aims to provide support for patients and help improve their quality of life.
Cheryl Pearse, Specialist Nurse in Smoking Cessation at UHSM, Manchester gives the Aspergillosis Patients Meeting a presentation on giving up smoking. July 2012
Travel Clinic Cardiff: Health Advice for International TravelersNX Healthcare
Travel Clinic Cardiff offers comprehensive travel health services, including vaccinations, travel advice, and preventive care for international travelers. Our expert team ensures you are well-prepared and protected for your journey, providing personalized consultations tailored to your destination. Conveniently located in Cardiff, we help you travel with confidence and peace of mind. Visit us: www.nxhealthcare.co.uk
Discover the benefits of homeopathic medicine for irregular periods with our guide on 5 common remedies. Learn how these natural treatments can help regulate menstrual cycles and improve overall menstrual health.
Visit Us: https://drdeepikashomeopathy.com/service/irregular-periods-treatment/
How to Control Your Asthma Tips by gokuldas hospital.Gokuldas Hospital
Respiratory issues like asthma are the most sensitive issue that is affecting millions worldwide. It hampers the daily activities leaving the body tired and breathless.
The key to a good grip on asthma is proper knowledge and management strategies. Understanding the patient-specific symptoms and carving out an effective treatment likewise is the best way to keep asthma under control.
Are you looking for a long-lasting solution to your missing tooth?
Dental implants are the most common type of method for replacing the missing tooth. Unlike dentures or bridges, implants are surgically placed in the jawbone. In layman’s terms, a dental implant is similar to the natural root of the tooth. It offers a stable foundation for the artificial tooth giving it the look, feel, and function similar to the natural tooth.
Breast cancer: Post menopausal endocrine therapyDr. Sumit KUMAR
Breast cancer in postmenopausal women with hormone receptor-positive (HR+) status is a common and complex condition that necessitates a multifaceted approach to management. HR+ breast cancer means that the cancer cells grow in response to hormones such as estrogen and progesterone. This subtype is prevalent among postmenopausal women and typically exhibits a more indolent course compared to other forms of breast cancer, which allows for a variety of treatment options.
Diagnosis and Staging
The diagnosis of HR+ breast cancer begins with clinical evaluation, imaging, and biopsy. Imaging modalities such as mammography, ultrasound, and MRI help in assessing the extent of the disease. Histopathological examination and immunohistochemical staining of the biopsy sample confirm the diagnosis and hormone receptor status by identifying the presence of estrogen receptors (ER) and progesterone receptors (PR) on the tumor cells.
Staging involves determining the size of the tumor (T), the involvement of regional lymph nodes (N), and the presence of distant metastasis (M). The American Joint Committee on Cancer (AJCC) staging system is commonly used. Accurate staging is critical as it guides treatment decisions.
Treatment Options
Endocrine Therapy
Endocrine therapy is the cornerstone of treatment for HR+ breast cancer in postmenopausal women. The primary goal is to reduce the levels of estrogen or block its effects on cancer cells. Commonly used agents include:
Selective Estrogen Receptor Modulators (SERMs): Tamoxifen is a SERM that binds to estrogen receptors, blocking estrogen from stimulating breast cancer cells. It is effective but may have side effects such as increased risk of endometrial cancer and thromboembolic events.
Aromatase Inhibitors (AIs): These drugs, including anastrozole, letrozole, and exemestane, lower estrogen levels by inhibiting the aromatase enzyme, which converts androgens to estrogen in peripheral tissues. AIs are generally preferred in postmenopausal women due to their efficacy and safety profile compared to tamoxifen.
Selective Estrogen Receptor Downregulators (SERDs): Fulvestrant is a SERD that degrades estrogen receptors and is used in cases where resistance to other endocrine therapies develops.
Combination Therapies
Combining endocrine therapy with other treatments enhances efficacy. Examples include:
Endocrine Therapy with CDK4/6 Inhibitors: Palbociclib, ribociclib, and abemaciclib are CDK4/6 inhibitors that, when combined with endocrine therapy, significantly improve progression-free survival in advanced HR+ breast cancer.
Endocrine Therapy with mTOR Inhibitors: Everolimus, an mTOR inhibitor, can be added to endocrine therapy for patients who have developed resistance to aromatase inhibitors.
Chemotherapy
Chemotherapy is generally reserved for patients with high-risk features, such as large tumor size, high-grade histology, or extensive lymph node involvement. Regimens often include anthracyclines and taxanes.
Nano-gold for Cancer Therapy chemistry investigatory projectSIVAVINAYAKPK
chemistry investigatory project
The development of nanogold-based cancer therapy could revolutionize oncology by providing a more targeted, less invasive treatment option. This project contributes to the growing body of research aimed at harnessing nanotechnology for medical applications, paving the way for future clinical trials and potential commercial applications.
Cancer remains one of the leading causes of death worldwide, prompting the need for innovative treatment methods. Nanotechnology offers promising new approaches, including the use of gold nanoparticles (nanogold) for targeted cancer therapy. Nanogold particles possess unique physical and chemical properties that make them suitable for drug delivery, imaging, and photothermal therapy.
“Psychiatry and the Humanities”: An Innovative Course at the University of Mo...Université de Montréal
“Psychiatry and the Humanities”: An Innovative Course at the University of Montreal Expanding the medical model to embrace the humanities. Link: https://www.psychiatrictimes.com/view/-psychiatry-and-the-humanities-an-innovative-course-at-the-university-of-montreal
STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7shruti jagirdar
Unit 4: MRA 103T Regulatory affairs
This guideline is directed principally toward new Molecular Entities that are
likely to have significant use in the elderly, either because the disease intended
to be treated is characteristically a disease of aging ( e.g., Alzheimer's disease) or
because the population to be treated is known to include substantial numbers of
geriatric patients (e.g., hypertension).
- Video recording of this lecture in English language: https://youtu.be/Pt1nA32sdHQ
- Video recording of this lecture in Arabic language: https://youtu.be/uFdc9F0rlP0
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Fungal Research Trust 20th Anniversary Meeting June 2011 - Professor David Denning
1. 20th Anniversary Meeting of the Fungal Research Trust Development of new antifungal drugs & combination therapy Professor David Denning June 2011 London, UK
2. Development of new antifungal drugs & combination therapy Professor David Denning Scientific Advisor Fungal Research Trust The University of Manchester The National Aspergillosis Centre
3. Priorities for novel antifungal agents for the treatment of invasive fungal infections Oral agent for treatment of systemic and mucosal candidiasis, with activity against all common Candida species (including fluconazole resistant strains). Parenteral/ oral agent with activity against Cryptococcus neoformans and penetration into the central nervous system Parenteral and oral agent with potent activity against Aspergillus spp., including triazole resistant species. Ideally there should be few drug interactions and safety in patients with renal or hepatic impairment. Parenteral and oral agent active against rare, but medically important moulds (e.g. Mucorales, Scedosporium spp.). Oral agent(s) for the treatment of chronic pulmonary and allergic aspergillosis, with few drug interactions (especially corticosteroids) and favourable intrapulmonary pharmacokinetics.
7. Priorities for novel antifungal agents for the treatment of invasive fungal infections Oral agent for treatment of systemic and mucosal candidiasis, with activity against all common Candida species (including fluconazole resistant strains). Parenteral/ oral agent with activity against Cryptococcus neoformans and penetration into the central nervous system Parenteral and oral agent with potent activity against Aspergillus spp., including triazole resistant species. Ideally there should be few drug interactions and safety in patients with renal or hepatic impairment. Parenteral and oral agent active against rare, but medically important moulds (e.g. Mucorales, Scedosporium spp.). Oral agent(s) for the treatment of chronic pulmonary and allergic aspergillosis, with few drug interactions (especially corticosteroids) and favourable intrapulmonary pharmacokinetics.
8. Mechanism of drug action Only 4 mechanisms of action and only the azoles and flucytosine are oral
9.
10. Importance of getting treatment right in candidaemia 100 P=0.02 73 Survival (%) 44 Yes No Empirical therapy correct? Parkins, J Antimicrob Chemother 2007;60:613.
11. Micafungin versus Ambisome randomised study Important to monitor blood cultures during therapy Unpublished data Kuse, Lancet 2007;369:1519
13. Laboratory surveillance of candidaemia age distribution 2008 Voluntary surveillance of candidaemia in England, Wales, & N. Ireland: 2008
14. Fluconazole insensitive or resistant Candidaemia - species distribution 2008 Echinocandin insensitive or resistant
15.
16.
17.
18. IV & oral antifungal with activity against Cryptococcus and penetration into the central nervous system
19.
20. Combination therapy – invasive aspergillosis Retrospective AmB failures Most HSCT 30/47 proven IA Multivariate analysis P=0.008 for combination and survival Curves came together later Marr et al, Clin Infect Dis 2004:39:797
21.
22. IV & oral antifungal with activity against Cryptococcus and penetration into the central nervous system
23. IV & oral antifungal with potent activity against Aspergillus spp., including triazole resistant species. Ideally there should be few drug interactions and safety in patients with renal or hepatic impairment.
24.
25. Acneiform rash with posaconazole Within 48hrs of commencing posaconazole he developed a severe acne-like rash, typical of folliculitis, across his face. His treatment had to stop, and we have n more oral treatments available for him. Unpublished
26. Patient LT LT (♀, age 49) lifelong asthma and atopy, with ABPA diagnosed in 1993. Recognised to have CPA complicating ABPA in 2001, but the CPA diagnosis was apparent in 1993. www.aspergillus.org.uk
27. Patient LT Better pulmonary status on voriconazole initially, but then slow deterioration, On 4l/min oxygen dependent 24 hours a day. Mild photosensitivity on voriconazole, even with little sun exposure. As wheelchair bound very little outside time, so mostly indoor light. She developed rough scaly patches over her face, neck and lower arms. Dermatological review indicated “multiple solar keratoses”. www.aspergillus.org.uk
28. Patient LT Skin biopsy from the right forearm showed low grade premalignant change. She was treated with local 5-fluorouracil cream (Efudix) (3 cycles) to the affected lesions. www.aspergillus.org.uk
31. Patient LT These photos were taken when her skin was at its worst. The inflammation resolved after discontinuing the cream. This reaction is expected with application of this mild chemotherapy agent. Following treatment her skin was much softer and considerably improved. Voriconazole has been stopped, and posaconazole substituted.
32. Patient LT 18 months later, new lesion on her forearm. Biopsy showed squamous cell carcinoma in situ. So voriconazole is a potent photosensitising drug with malignant potential